Optimized polyepitope neoantigen DNA vaccines elicit neoantigen-specific immune responses in preclinical models and in clinical translation

Keyphrases

• Neoantigen 100%
• Clinical Translation 100%
• Specific Immune Response 100%
• DNA Vaccine 100%
• Polyepitope 100%
• Vaccine Platform 15%
• Polyepitope DNA Vaccine 10%
• Metastatic Pancreatic Neuroendocrine Tumour 10%
• Targeting Cancer 5%
• Antigen Presentation 5%
• Immune Response 5%
• Epitope 5%
• Genome Sequencing 5%
• N-terminus 5%
• Breast Tumor 5%
• Tumor Immunity 5%
• Monitoring Data 5%
• Immunogenic 5%
• Immunogenicity 5%
• Specific Response 5%
• Ubiquitin 5%
• Breast Cancer Model 5%
• Early Phase Clinical Trials 5%
• Vaccine Design 5%
• Antitumor Immune Response 5%
• Personalized Cancer Therapy 5%
• Immune Monitoring 5%
• Antigen-specific T Cell Response 5%
• Antigen Processing 5%
• In Silico 5%
• Design Optimization 5%
• Model Antigen 5%
• Mutant Forms 5%
• E0771 5%
• Cancer Neoantigens 5%
• Neoantigen Prediction 5%
• DNA Testing 5%
• Immune Checkpoint Therapy 5%
• Synthetic Long Peptide Vaccine 5%
• Prediction pipeline 5%

Immunology and Microbiology

• Immune Response 100%
• Neoantigen 100%
• DNA Immunization 100%
• Antigen Presentation 9%
• T Cell 4%
• Epitope 4%
• Amino Terminal Sequence 4%
• Cancer Immunotherapy 4%
• Preclinical Study 4%
• Immunogenicity 4%
• Genome Sequencing 4%
• Immune Checkpoint Blockade 4%
• Peptide Vaccine 4%
• Ubiquitins 4%
• In Vitro 4%